Evidence map›Paper›PMID 34783233›Full record

ArticleEuropean journal of histochemistry : EJH2021

LncRNA FGD5-AS1 functions as an oncogene to upregulate GTPBP4 expression by sponging miR-873-5p in hepatocellular carcinoma.

Nuobei Zhang, Hao Shen, Shenan Huang, Fenfen Wang, Huifang Liu, Fen Xie, Lei Jiang, Xin Chen

Open access · goldAbstract read
In one paragraph

Article in European journal of histochemistry : EJH, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Nuobei ZhangDepartment of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang. znbicx@163.com.
Hao ShenDepartment of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang. 83866161@qq.com.
Shenan HuangDepartment of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang. 4417760@qq.com.
Fenfen WangDepartment of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang. 553266419@qq.com.
Huifang LiuDepartment of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang. 623806969@qq.com.
Fen XieDepartment of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang. fener87@126.com.
Lei JiangDepartment of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang. 15083804061@163.com.
Xin ChenDepartment of Nuclear Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang. xinchen13870979404@gmx.com.
Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The long non-coding FGD5-AS1 (LncFGD5-AS1) has been reported to be a novel carcinogenic gene and participant in regulating tumor progression by sponging microRNAs (miRNAs). However, the pattern of expression and the biological role of FGD5-AS1 in hepatocellular carcinoma (HCC) remains largely unknown. The expression level of FGD5-AS1 in tumor tissues and cell lines was measured by RT-qPCR. CCK-8, EdU, flow cytometry, wound healing, and transwell chamber assays were performed to investigate the role of FGD5-AS1 in cell proliferation, apoptosis, migration, and invasion in HCC. Dual luciferase reporter, and RNA pull-down assays were performed to identify the regulatory interactions among FGD5-AS1, miR-873-5p and GTP-binding protein 4 (GTPBP4). We found that the expression of FGD5-AS1 was upregulated in HCC tissues and cell lines. Moreover, the knockdown of FGD5-AS1 suppressed cell proliferation, migration and invasion, and induced apoptosis in HCC cells. Further studies demonstrated that FGD5-AS1 could function as a competitive RNA by sponging miR-873-5p in HCC cells. Moreover, GTPBP4 was identified as direct downstream target of miR-873-5p in HCC cells and FGD5-AS1mediated the effects of GTPBP4 by competitively binding with miR-873-5p. Taken together, this study demonstrated the regulatory role of FGD5-AS1 in the progression of HCC and identified the miR-873-5p/GTPBP4 axis as the direct downstream pathway. It represents a promising novel therapeutic strategy for HCC patients.

Indexed as

Gene Expression Regulation, NeoplasticOncogenesUp-RegulationCarcinoma, HepatocellularGTP-Binding ProteinsHep G2 CellsHumansLiver NeoplasmsMicroRNAsNeoplasm ProteinsNuclear ProteinsRNA, Long NoncodingRNA, NeoplasmGTP-Binding ProteinsGTPBP4 protein, humanMicroRNAsMIRN873 microRNA, humanNeoplasm ProteinsNuclear ProteinsRNA, Long NoncodingRNA, Neoplasm

Identifiers

PMID34783233
PMCPMC8611415
OpenAlexW3212163368

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.